Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

. . . Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 July 08, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp. Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, t ...